Oppenheimer Maintains Outperform on Lumos Pharma, Lowers Price Target to $17
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Leland Gershell has maintained an Outperform rating on Lumos Pharma (NASDAQ:LUMO), but lowered the price target from $18 to $17.
August 10, 2023 | 3:49 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Lumos Pharma's price target has been lowered from $18 to $17 by Oppenheimer, though the Outperform rating is maintained.
The lowering of the price target by Oppenheimer could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained Outperform rating indicates that the analyst still sees potential upside, which could counterbalance the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100